Navigation Links
Lilly Statement on PDUFA Vote by Senate
Date:6/26/2012

INDIANAPOLIS, June 26, 2012 /PRNewswire/ -- Following is a statement from John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY), regarding today's Senate vote on S.3187 to reauthorize the Prescription Drug User Fee Act (PDUFA):

"The vote to reauthorize PDUFA is a welcome development and represents an important step forward for medical innovation.

"Thanks to broad bipartisan support of Congress, the FDA will continue to have the necessary resources to review potential new treatments. The new law will make the review process more timely, balanced and efficient, including a strengthened framework for evaluating the benefits and risks of new treatments.

"Since its inception in 1992, PDUFA has enabled the FDA to shorten review time from new drug applications by 60 percent. As a result, patients in the U.S. have had speedier access to more than 1,500 new medicines to treat medical conditions such as cancer, diabetes, cardiovascular disease, and neurological disorders.

"PDUFA will keep our nation at the forefront of medical innovation and allow us to continue delivering new medicines that help patients live longer, healthier, and more productive lives. We look forward to the President's signature on this legislation."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
2. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
3. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
4. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
5. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
6. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
7. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
8. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
9. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
10. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)...  Amy Baxter MD, chief executive officer and founder ... relief, was awarded a 2017 Top 40 Healthcare Transformer ... at the MM&M Top 40 Healthcare Transformers dinner and ... on May 10, 2017. The dinner followed a full-day ... the pill."  "Innovation goes beyond invention," noted ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading ... , published its 2017 ranking of the Best-Equipped Hospitals ... data analysis from GHI,s hospitals database for Latin America ... region. The GHI database covers 86% of the hospitals in ... data points for each institution in key areas such as ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, May 17, ... lead singers in the rock industry would take his own life, but the extremely talented ... mental illness played a role in the death of Chris Cornell . , Depression ...
(Date:5/21/2017)... (PRWEB) , ... May 20, 2017 , ... Pot. Reefer. ... find it, review it, and share its attributes like never before. More than a ... to connect cannabis enthusiasts to stores, strains, products – and for the first time ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from ... follow a protocol to quickly identify and treat the condition. , The mandate ... have saved Rory or anyone else’s life. , Now, five years after the ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... an upcoming episode of Innovations with Ed Begley, Jr., airing fourth quarter 2017 ... distributor of a clean, organic dietary supplement made from naturally occurring ingredients. Innovations ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller ... assistance to families and business owners in the region, is embarking on a ... sufferers and their families. , Multiple sclerosis (MS) is a demyelinating disease that ...
Breaking Medicine News(10 mins):